Carrie Kitko
Pediatric Hematology-Oncology · Nashville, TNNPI 1205912177
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $37,937 of the $50,599 with a category attached, or 75.0%. 12 manufacturers reported payments, led by Incyte Corporation at 32.4% of the total. Among pediatric hematology-oncology clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 61 payments — averaging $829.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$16K
- Sanofi-aventis U.S. LLC$13K
- CSL Behring$10K
- Amgen$5K
- Mesoblast, Inc.$3K
- Adaptive Biotechnologies Corporation$2K
- plus $1K from 6 others
Across 169 payments — averaging $5478.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$305K
- Jazz Pharmaceuticals Inc.$190K
- Syndax Pharmaceuticals, Inc.$122K
- Incyte Corporation$108K
- Kadmon Corporation LLC$45K
- Sanofi US Services Inc.$43K
- plus $115K from 6 others
What the payments were for
- Consulting fees$37,93775%
- Speaking & faculty fees$6,62213%
- Travel & lodging$2,9956%
- Food & beverage$3,0446%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 22 | $16,407 |
| Sanofi-aventis U.S. LLC | 6 | $12,824 |
| CSL Behring | 2 | $10,200 |
| Amgen | 1 | $4,650 |
| Mesoblast, Inc. | 1 | $3,125 |
| Adaptive Biotechnologies Corporation | 14 | $1,893 |
| Novartis | 6 | $507 |
| Jazz Pharmaceuticals Inc. | 4 | $491 |
| Gilead | 2 | $187 |
| Syndax Pharmaceuticals, Inc. | 1 | $135 |
| Kadmon Pharmaceuticals LLC | 1 | $105 |
| Sanofi | 1 | $74 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$50,599 in reported general payments places this provider in the 90th percentile of 113 pediatric hematology-oncology providers in Tennessee.
See all pediatric hematology-oncology providers in Tennessee →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RezurockBelumosudil Mesylate | 12 | $431,150 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sanofi-aventis U.S. LLCRezurock | $12,824 | $431,15012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 113 pediatric hematology-oncology providers in Tennessee.
Other pediatric hematology-oncology in Nashville
- Jennifer DommNashville$359K
- Haydar FrangoulNashville$356K
- Michael DebaunNashville$39K
- Alexandra BorstNashville$27K
- James ConnellyNashville$21K
- Scott BorinsteinNashville$21K
- Clinton CarrollNashville$8K
- Heather McDanielNashville$8K
- Elizabeth YangNashville$7K
- Meghann McManusNashville$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.